Human nasopharyngeal carcinoma: in situ hybridization for Epstein-Barr virus (EBV) encoded RNA (EBER) using NCL-EBV. Note intense staining of EBV-infected cells. Paraffin section.

Manual EBV Probe

Antigen Background

EBV infection is associated with a variety of pathological conditions. The virus has been reported to be demonstrated in infectious mononucleosis, Burkitt's lymphoma, the Reed Sternberg cells of Hodgkin's disease and in nasopharyngeal carcinoma. In HIV infection, EBV has also been reported to be demonstrated in primary CNS lymphomas and oral hairy leukoplakia lesions. NCL-EBV is a fluorescein-labelled oligonucleotide cocktail of probes designed to demonstrate cells latently-infected with EBV. The probe hybridizes to abundantly expressed Epstein-Barr virus-encoded RNA (EBER) transcripts which are concentrated in the nuclei of latently-infected cells. These transcripts are thought to block the activation of dsRNA-dependent eukaryotic initiation factor 2a (elF-2a) protein kinase DAI. In the absence of EBER, elF-2a inhibits cellular protein synthesis.

Recently Viewed